Prospective drug safety monitoring using the UK primary-care general practice research database: Theoretical framework, feasibility analysis and extrapolation to future scenarios

Drug Safety

Volumn 33, Issue 3, 2010, Pages 223-232

  Johansson, Saga ^a   Wallander, Mari Ann ^b   De Abajo, Francisco J ^c,d   Rodríguez, Luis Alberto García ^e  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Department of Human Use Medicines   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e Department of Pharmacoepidemiology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUDESONIDE PLUS FORMOTEROL; DULOXETINE; EZETIMIBE; GAMMA GLUTAMYLTRANSFERASE; METFORMIN PLUS ROSIGLITAZONE; MICROSOMAL AMINOPEPTIDASE; TADALAFIL; TIOTROPIUM BROMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONCEPTUAL FRAMEWORK; DATA BASE; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEASIBILITY STUDY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL PRACTICE; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

ACUTE DISEASE; BRAIN ISCHEMIA; CONSUMER PRODUCT SAFETY; DATABASES, FACTUAL; DRUG MONITORING; DRUG TOXICITY; ELECTRONIC HEALTH RECORDS; FAMILY PRACTICE; FEASIBILITY STUDIES; FIBRINOLYTIC AGENTS; FORECASTING; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MEDICAL AUDIT; PATIENT SELECTION; PRIMARY HEALTH CARE; PSYCHOLOGICAL TECHNIQUES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 76949084445     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11319010-000000000-00000     Document Type: Article

References (18)

1. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007; 167 (16): 1752-1759
2. Strom BL. Pharmacoepidemiology. 4th ed. London: John Wiley & Sons, 2005
3. De Abajo FJ. Improving pharmacovigilance beyond spon-taneous reporting. Int J Pharmaceut Med 2005; 19 (4): 209-218
4. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12 (1): 17-29
5. European Commission: Enterprise and Industry. Rules governing medicinal products in the European Union: guidelines on pharmacovigilance for medicinal products for human use [online]. Available from URL: http://ec.europa.eu/ enterprise/pharmaceuticals/eudralex/vol9-en. htm [Accessed 2009 Dec 21]
6. European Commission: Innovative Medicines Initiative. The Innovative Medicines Initiative (IMI) strategic research agenda: creating biomedical R&D leadership for Europe to benefit patients and society [online]. Available from URL: http://imi.europa.eu/docs/imi-gb-006v2 15022008-research- agenda-en.pdf [Accessed 2009 Dec 21]
7. Institute of Medicine of the National Academies. The future of drug safety. promoting and protecting the health of the public. Washington, DC: The National Academies Press, 2007
8. Jick H, Jick SS, Derby LE. Validation ofinformation recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302 (6779): 766-768
9. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepide-miology. Br J Clin Pharmacol 1998; 45 (5): 419-425
10. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23 (5): 686-689
11. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997; Spring (87): 36-40
12. Lucena MI, Garcia-Cortes M, Cueto R, et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008; 22 (2): 141-158
13. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11 (2): 272-276
14. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156 (12): 1327-1332
15. De Abajo FJ, Montero D, Madurga M, et al. Acute and clini-cally relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58 (1): 71-80
16. Garcia Rodriguez LA, Ruigomez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy 1997; 17 (4): 721-728
17. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983; 249 (13): 1743-1745
18. Cooper AJ, Lettis S, Chapman CL, et al. Developing tools for the safety specification in risk management plans: lessons learned from a pilot project. Pharmacoepidemiol Drug Saf 2008; 17 (5): 445-454